FDA Accepts Biohaven Drug Application for SCA Treatment
The agency moves toward a 2027 decision on the first potential treatment for spinocerebellar ataxia.
Updated on Oct. 22, 2026 in Alzheimer’s
Live Poll
Should the FDA prioritize faster approval for rare disease treatments over strict trial design requirements?
The FDA has accepted Biohaven’s resubmitted new drug application for troriluzole, a potential treatment for spinocerebellar ataxia. The move follows the submission of new supportive analyses aimed at addressing previous regulatory concerns regarding trial design.
Why it matters
Spinocerebellar ataxia currently has no FDA-approved treatments, making the path toward this drug’s approval a significant potential milestone for patients. The FDA plans to conduct an advisory committee meeting before reaching a final decision by the first quarter of 2027.
The application addresses roughly 6,000 patients in North America currently living without an FDA-approved treatment option. The FDA has set a user fee goal date for the first quarter of 2027 to finalize its review.
The players
Biohaven
This New Haven, Connecticut-based biopharmaceutical company focuses on developing innovative therapies for neurological and neuropsychiatric diseases.
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
The details
Troriluzole works by reducing synaptic levels of glutamate by augmenting excitatory amino acid transporters on glial cells. Biohaven’s resubmission includes additional data intended to resolve previous FDA objections related to the drug's clinical trial design.
Timeline
2023: The FDA issued a refuse to file letter to Biohaven.
November 2025: The FDA issued a complete response letter regarding the drug application.
October 22, 2026: Biohaven shares rose by 25% following the news.
Q1 2027: The FDA target date for a final decision on approval.
Health Landscape
The FDA's New Drug Application (NDA) review process remains a rigorous barrier for companies seeking to bring breakthrough therapies to market. This development underscores the common industry hurdle of navigating regulatory feedback cycles to secure approval for rare disease treatments.
Patients currently managing spinocerebellar ataxia may gain access to the first specialized treatment if the FDA grants final approval. This process directly impacts the future availability of therapeutic options for individuals currently limited to symptom management.
The takeaway
This news highlights the persistence required to navigate the federal drug approval process for rare conditions. Investors and patients should monitor the upcoming advisory committee meeting for definitive insights into the drug's path to market.
What happens next
The FDA will host an advisory committee meeting prior to the first quarter of 2027 to further evaluate the clinical data provided in the resubmission.
Further reading
Learn more about the latest developments in neurodegenerative research on our Alzheimer’s section.
Source note: This article includes information reported by Bio World.
Live Poll
Should the FDA prioritize faster approval for rare disease treatments over strict trial design requirements?
